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Abstract: High tibial osteotomy (HTO) is an effective alternative for medial compartmental knee
osteoarthritis (OA). Circulating microRNAs (miRNAs) are known to serve as OA-related biomarkers.
The present study investigated the differential expression of serum miRNAs before and after HTO
to identify potential miRNAs as prognostic biomarkers. miRNA-polymerase chain reaction (PCR)
arrays were used to screen for miRNAs in the serum at preoperative and 6-month postoperative
time points from six patients, and the differentially expressed miRNAs identified in the profiling
stage were validated using real-time PCR at post-operative months 6 and 18 in 27 other HTO-treated
patients. Among 84 miRNAs involved in the inflammatory process, three (miR-19b-3p, miR-29c-3p,
and miR-424-5p) showed differential expression patterns in the profiling stage (p = 0.011, 0.015,
and 0.021, respectively). Levels of these three and four other miRNAs (miR-140-3p, miR-454-3p,
miR-let-7e-5p, and miR-885-5p) known to be related to OA progression were evaluated in the serum
of 27 patients. Only four miRNAs (miR-19b-3p, miR-140-3p, miR-454-3p, and miR-let-7e-5p) were
significantly upregulated at postoperative month 6 (p = 0.003, 0.005, 0.004, and 0.004, respectively),
and only miR-140-3p was significantly upregulated up to 18 months after operation (p = 0.003).
Together, this study reveals the significantly upregulated serum miRNAs after HTO as potential
prognostic biomarkers; however, further studies are warranted to elucidate their clinical implications.
Keywords: knee; medial compartmental osteoarthritis; high tibial osteotomy; serum miRNA; prog-
nosis
1. Introduction
Osteoarthritis (OA) is degenerative joint disease related to functional disability with
age. Progression of injured articular cartilage is an irreversible process, leading to its per-
manent damage. OA prevalence is increasing in the aging population, and OA treatment is
a huge burden on the healthcare system worldwide [1]. In patients with medial compart-
mental OA with varus alignment, high tibial osteotomy (HTO) is a well-known reliable
treatment modality [2,3]. Arthroscopic findings in several clinical studies have revealed
repair process of the degenerated cartilage following realignment of the mechanical axis of
the lower leg. HTO in medial compartmental knee OA offers excellent intermediate and
long-term survival [4–6].
The pathogenesis of OA is considered a multifactorial and complex process mediated
by a close interaction among genetic, mechanical, and environmental factors. The effects of
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dysregulation at the gene level during the pathogenic process of OA have recently been
documented.
MicroRNAs (miRNAs) are small non-coding RNAs comprising 19–25 nucleotides
that regulate gene expression post-transcriptionally through mRNA degradation or trans-
lational suppression by binding to the 3′-untranslated region of target genes [7]. The
roles of miRNAs in cartilage degeneration have recently been reported [8,9]. Most studies
that quantified miRNA expression in OA have focused on cartilage or cell lines from the
tissue. However, miRNAs are also detected in circulatory body fluids of patients with
other pathologies [10,11]. Some studies have demonstrated the association between levels
of some circulating miRNAs and diagnosis/prognosis of several diseases, and highlighted
their role as potential biomarkers [9,12,13].
Most studies on HTO in medial compartmental knee OA have focused on clinical
outcomes in terms of change in the mechanical load on the knee joint resulting from
the realignment of the mechanical axis [14–16]. Regeneration of degenerated articular
cartilage in the medial compartmental knee OA can be expected following HTO without
any additional procedures, although the detailed mechanism is still unclear [17]. Despite
several studies related to HTO in medial compartmental knee OA and miRNA expression
in OA, little is known about the changes in miRNA expression patterns after HTO in medial
compartmental knee OA and their clinical implications.
Our previous study revealed significant alterations in the miRNA expression in the
synovial fluid (SF) after HTO in medial compartmental knee OA; this effect may be po-
tentially related to clinical and radiographic improvements and subsequent cartilage
regeneration [18]. Dysregulated expression of miRNAs in SF has been related to cartilage
degradation during OA progression. Significant changes in SF miRNAs after HTO in
medical compartmental knee OA may be important findings to predict OA prognosis
after HTO. However, obtaining SF aspirate may be invasive and complicated, and require
several cumbersome processes. Therefore, this prospective study was conducted to detect
serum miRNAs as potential biomarkers for prognosis after HTO. Identification of circulat-
ing serum miRNAs with significantly altered expression patterns after HTO would be a
promising strategy to highlight their role as biomarkers to evaluate prognosis and clinical
and radiological improvement.
2. Materials and Methods
2.1. Study Subjects
Patients with medial compartmental knee OA who underwent medial open-wedge
HTO between November 2015 and February 2017 were prospectively enrolled in this study.
This study was approved by the Institutional Review Board of Hallym University Sacred
Heart Hospital (protocol code: 2015-I101, Date: 12 October 2015).
Patients who met the following inclusion criteria were finally enrolled in this study:
(1) medial compartmental knee OA confirmed on plain radiographs including Rosenberg
and long standing views (2) no ligament injuries and lateral meniscus tear on MRI and
intraoperative arthroscopic finding (3) no degenerative diseases diagnosed on other joints
and spine. All patients had degenerative tear of medial meniscus accompanied by medial
compartmental knee OA, confirmed on MRI and intraoperative arthroscopic finding,
although the tear site and pattern were slightly different for each patient.
Six patients were recruited for the profiling stage, all of which were female with a
mean age of 57.7 years (52 to 65 years). (Table 1). All patients were Kellgren–Lawrence
grade (K-L grade) II or III OA only in the medial compartment of the affected knee.
Validation of the miRNAs profiled was carried out by recruiting 27 patients, including
21 female and 6 male patients with a mean age of 57.4 years (46 to 65 years). All patients
were K-L grade II or III OA only in the medial compartment. Serum specimens were
collected from each patient prior to HTO and at 6-month follow-up (Figure 1). Serum
specimens were additionally collected at an outpatient clinic 18 months after surgery in
20 patients who agreed to participate in an 18-month follow-up study (Table 2).
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Total Pain Stiffness Function
1 F 57 28.4 II 6 54 13 4 37
2 F 55 23.9 II 5 10 1 0 9
3 F 61 22.8 III 7 56 8 6 42
4 F 56 27.9 III 7 42 9 3 30
5 F 65 30.2 III 3 14 0 0 14
6 F 52 26.0 III 4 33 9 3 21
WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.
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Figure 1. Study design. Three candidate miRNAs were identified in the serum from six patients 
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pression together with other four previously identified miRNAs (total seven miRNAs) in 27 patients 
at postoperative 6 months and 20 patients at postoperative 18 months for validation. Data of seven 
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Figure 1. Study design. Three candidate miRNAs were identified in the serum from six patients with
high tibial osteotomy at preoperative and postoperative time points. We evaluated their expression
together with other four previously identified miRNAs (total seven miRNAs) in 27 patients at
postoperative 6 months and 20 patients at postoperative 18 months for validation. Data of seven
patients were excluded, owing to different collection time points.
Clinical assessment for pain and functional improvement was performed using a
visual analogue scale (VAS) score and the Western Ontario McMaster Universities Os-
teoarthritis Index (WOMAC) score, both preoperatively and 6 and 18 months after surgery.
Radiological evaluation was performed using standing full-length anteroposterior radio-
graphs of the lower limbs taken preoperatively and 6 months after surgery in all cases.
These radiographs were obtained to ensure that the patella was directly facing the front.
Radiographic changes after HTO were evaluated by measuring the mechanical axis and
weight-bearing line (WBL) ratio, which was defined as the perpendicular distance from the
WBL to the medial edge of the tibial plateau divided by the width of the tibial plateau. The
mechanical axis was defined as the angle subtended by a line drawn from the centre of the
femoral head to the centre of the knee and a line drawn from the centre of the knee to the
centre of the talus. The WBL was drawn from the centre of the femoral head to the centre
of the superior articular surface of the talus [19].
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Total Pain Stiffness Function
1 F 57 23.4 III 6 14 3 2 9
2 1 F 58 30.1 II 3 6 2 0 4
3 2 F 50 30.5 III 3 21 2 2 17
4 3 F 46 33.3 III 7 22 3 2 17
5 F 54 26.5 II 7 26 5 2 19
6 4 F 51 25.5 II 9 59 14 3 42
7 F 56 21.8 III 8 28 5 5 18
8 F 57 28.4 II 6 54 13 4 37
9 5 F 55 23.9 II 5 10 1 0 9
10 6 F 61 22.8 III 7 56 8 6 42
11 7 F 56 27.9 III 7 42 9 3 30
12 F 52 26 III 4 33 9 3 21
13 8 M 64 30.9 III 7 30 7 2 21
14 F 55 24 III 8 48 10 4 34
15 9 F 56 26.4 III 7 52 9 6 37
16 10 M 61 28.5 III 8 53 12 3 38
17 11 F 59 26.3 III 5 36 8 3 25
18 12 F 56 27.5 III 5 42 15 6 21
19 13 F 61 29.7 III 8 61 13 6 42
20 14 F 57 31.2 III 6 45 10 4 31
21 M 58 25.4 III 5 23 7 3 13
22 15 F 56 21.8 III 3 29 5 2 22
23 16 F 56 25.4 III 2 26 5 2 19
24 17 M 59 24.8 III 8 37 7 4 26
25 18 F 60 25.2 III 7 37 2 4 41
26 19 M 64 25.7 III 7 42 5 0 37
27 20 M 56 25.4 III 4 25 4 3 18
HTO: high tibial osteotomy.
2.2. Sampling Strategy and miRNA Analysis
2.2.1. Sample Collection and RNA Extraction from the Serum
First, 10 mL blood samples were collected from all patients and the serum was sep-
arated by centrifugation of blood samples within 4 h of collection to ensure consistent
pre-analytical conditions. Centrifugation was performed for 10 min at 1900× g and 4 ◦C,
followed by for 10 min a 16,000× g and 4 ◦C to completely remove cell debris. All serum
samples were aliquoted and immediately stored at −80 ◦C until investigation. Total RNA
was isolated from each specimen using the miRNeasy Serum/Plasma Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
2.2.2. Profiling by miRNA Array Analysis
Reverse transcription (RT) was conducted using 2 µL RNA in a 10 µL reaction using
miScript II RT kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.
The complementary DNA (cDNA) obtained from miRNA was amplified using the miScript
miRNA PCR Array (MIHS-105Z, Qiagen, Hilden, Germany). Real-time polymerase chain
reaction (RT-PCR) was performed on the StepOnePlusTM Real Time PCR System (Applied
Biosystems, Foster City, CA, USA) using the miScript SYBR Green PCR kit (Qiagen, Hilden,
Germany). Thermal cycling conditions were 95 ◦C for 15 min, followed by 40 cycles of
95 ◦C for 15 s, 55 ◦C for 30 s, and 70 ◦C for 30 s. The data were analysed using PCR
array data analysis tools (Qiagen, Hilden, Germany). These panels contained primers for
the detection of the 84 most highly expressed miRNAs in human body fluids. Real-time
PCR was performed according to the manufacturer’s instructions. In each 96-well plate,
cDNAs from serum samples obtained during preoperative and postoperative month-6 time
points from each patient were amplified in parallel. Expression values were calculated
using the 2−∆Ct method, and the mean and standard deviation of three technical replicates
were presented. In addition, fold changes indicating values of changes in the expression
of miRNAs between preoperative, postoperative 6-month, and postoperative 18-month
time points were calculated. This fold change (relative expression) was analysed using the
2−∆∆Ct method [20].
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2.2.3. Validation by Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR)
RT of total RNA (miRNAs) was performed using miScript II RT kit according to the
manufacturer’s instructions. Each 20 µL RT reaction contained 5 µL of extracted total RNA,
4 µL HiSpec buffer, 2 µL 10× nucleic mix, 2 µL of miScript RT enzyme. The reaction
was incubated for 60 min at 37 ◦C and 5 min at 95 ◦C. RT-qPCR was performed on the
StepOnePlusTM Real Time PCR System using the miScript SYBR-Green PCR kit in a total
reaction volume of 25 µL containing 2 µL cDNA (10× diluted). The miScript primer assays
(Qiagen, Hilden, Germany) used in this stage are listed in Table 3. The PCR thermal
parameters were as follows: A total of 15 min at 95 ◦C, 40 cycles of 15 s at 94 ◦C followed by
30 s at 55 ◦C, and 30 s at 70 ◦C. All qPCR reactions were run in triplicate for efficient test. To
normalize the expression of the miRNAs being validated, the GeNorm algorithm (GenEx,
Qiagen, Hilden, Germany) was used. SNORD61 was used as an endogenous reference
gene [21].
Table 3. Specific miScript primer assays used for RT-qPCR.
miRNA Symbol Assay ID Catalogue No. Sequencing
SNORD61 Hs_SNORD61_11 MS00033705
miR-19b-3p Hs_miR-19b_2 MS00031584 5′UGUGCAAAUCCAUGCAAAACUGA
miR-29c-3p Hs_miR-29c_1 MS00003269 5′UAGCACCAUUUGAAAUCGGUUA
miR-424-5p Hs_miR-424_1 MS00004186 5′CAGCAGCAAUUCAUGUUUUGAA
miR-140-3p Hs_miR-140-3p_1 MS00008673 5′UACCACAGGGUAGAACCACGG
miR-454-3p Hs_miR-454_1 MS00007861 5′UAGUGCAAUAUUGCUUAUAGGGU
miR-let-7e-5p Hs_let-7e_3 MS00031227 5′UGAGGUAGGAGGUUGUAUAGUU
miR-885-5p Hs_miR-885-5p_1 MS00010668 5′UCCAUUACACUACCCUGCCUCU
2.2.4. Chemicals
The manufactured kits containing the chemicals required for each procedure according
to the standard protocol provided by the manufacturer’s introductions. Reagents other
than these kits were rarely used in the current study.
The chemicals and assay kits used for each procedure were summarized in Table 4.
Table 4. Chemicals or assay kits used in this study.
Procedure Chemical/Assay Kit
RNA preparation
miRNeasy Serum/Plasma kit (Qiagen)
miRNeasy Serum/Plasma Spike-In Control (Qiagen)
QIAzol Lysis Reagent (Qiagen)
Absolute Ethanol (Merck)
Chloroform (without added isoamyl alcohol) (Sigma)
PCR array miScript miRNA PCR array (MIHS-105Z) (Qiagen)
Reverse Transcription miScript II RT kit (Qiagen)
Real-Time PCR miScript SYBR Green PCR kit (Qiagen)Specific primer assays (Table 3)
2.2.5. Data Analysis and Statistical Methods
Statistical analyses were performed using SPSS 23.0 software (IBM Corp., Armonk,
NY, USA). Paired t-test for miRNA level analysis (∆Ct) and a nominal p-value < 0.05
were used in the profiling stage, and Bonferroni corrected p-value (0.05/7) was used in
the validation stage. To compare changes in postoperative levels of miRNAs associated
with clinical and radiologic outcomes, a correlation analysis was performed using the
Spearman rank test considering covariates, including age, gender, body mass index, preop-
erative K-L grade, and preoperative lower leg alignment. Wilcoxon signed-rank test was
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used for the comparison of clinical and radiological outcomes between preoperative and
postoperative values.
3. Results
3.1. Identification of Differentially Expressed miRNAs in the Profiling Stage
A panel of 84 miRNAs and controls were profiled in the serum specimens obtained
from six patients with medial compartment knee OA. The results of the expression of
these 84 miRNAs based on biological groups are shown as a heat map (Figure 2). PCR
array analysis revealed the expression of 34 of 84 target miRNAs in all serum specimens
(Table S1; Supplementary Material). Only three miRNAs, namely, miR-19b-3p, miR-29c-3p,
and miR-424-5p, were upregulated with a significant fold change (Table 5). Hence, these
were included in the validation stage.
Table 5. 3 miRNAs showing significant fold change at profiling stage.
miRNA
Preop. Postop. Month 6 Fold
Regulation
p-Value *
∆Ct 2−∆Ct ∆Ct 2−∆Ct
hsa-miR-19b-3p −0.66 ± 0.87 1.57 −2.47 ± 1.38 5.53 3.51 0.011
hsa-miR-29c-3p −0.32 ± 0.79 1.25 −2.10 ± 1.26 4.28 3.43 0.015
hsa-miR-424-5p −0.48 ± 1.17 1.39 −2.23 ± 0.80 4.69 3.37 0.021
Values are presented as the mean ± standard deviation. * p < 0.05.
3.2. Validation Stage: Serum Expression Levels of Seven miRNAs at Preoperative and
Postoperative Month-6 Time Points in 27 Patients Who Underwent Open Wedge HTO
To validate our profiling results, the expression of seven miRNAs, the three miRNAs
detected in the profiling stage and four other miRNAs (miR-140-3p, miR-454-3p, miR-let-
7e-5p, and miR-885-5p) previously reported to be related to OA progression, was measured
in the serum at preoperative and postoperative month-6 time points in 27 patients using
RT-qPCR. Of them, four (miR-19b-3p, miR-140-3p, miR-454-3p, and miR-let-7e-5p) miRNAs
showed differential expression patterns between 6 months after surgery and pre-operative
time points following normalization with SNORD61 expression (Figure 3). We corrected
the p-values using the Bonferroni method, and found that one miRNA (miR-19b-3p) from
our profiling result and three miRNAs (miR-140-3p, miR-454-3p, and miR-let-7e-5p) from
previous studies showed significant positive fold changes (Table 6). Raw data from all
patients prior to HTO and 6 and 18 months after HTO are available in Supplement Figure S1.
Table 6. Fold changes in the expression of seven miRNAs at profiling and validation stages. Data
from the validation stage were collected 6 months after surgery.
miRNA
Profiling Stage
Using Microarray p-Values *
Validation Stage Using
Real-Time PCR p-Values *
Fold Change Fold Change
has-miR-19b-3p 3.51 0.011 3.66 0.003 **
has-miR-29c-3p 3.43 0.015 3.68 0.01
has-miR-424-5p 3.37 0.021 5.49 0.063
has-miR-140-3p - - 4.12 0.005 **
has-miR-454-3p - - 2.18 0.004 **
has-miR-let-7e-5p - - 2.38 0.004 **
has-miR-885-5p - - 2.06 0.096
* Paired t-test. ** indicates a Bonferroni-corrected p-value < 0.0071 (0.05/7) corresponding to the statistical
significance.
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Figure 3. Box plot showing the interquartile range and median values of the expression levels of
miR-19b-3p (A), miR-29c-3p (B), miR-424-5p (C), miR-140-3p (D), miR-454-3p (E), miR-let-7 -5p (F),
and miR-885-5p (G) before surgery and 6 months after surgery at the validation stage. The values
represent the relative levels normalized to the level of the reference gene, SNORD61. ** indicates a
Bonferroni-corrected p-value < 0.0071 (0.05/7) corresponding to the statistical significance.
3.3. Comparison of Clinical and Radiological Outcomes between Preoperative and Postoperative
Month-6 Time Points in 27 Patients
Clinical outcomes assessed using a VAS and WOMAC questionnaire were signifi-
cantly improved 6 months after surgery as compared with those reported before operation
(Table 7). Preoperative pain, functional disability, and lower leg alignment showed signifi-
cant improvements 6 months after index surgery in 27 patients.
Table 7. Improvements in radiological and functional outcomes in 27 patients at 6 months af-
ter surgery.
Variables Preoperative Postoperative Month-6 p-Value *
Mechanical axis
(−: varus, +: valgus) −5.0 ± 2.2 +2.5 ± 1.5 <0.001
Weight-bearing line ratio (%) 18.6 ± 6.2 59.5 ± 8.2 <0.001
Visual analogue scale 6.0 ± 1.9 2.6 ± 1.1 <0.001
WOMAC total 36.4 ± 16.0 24.2 ± 11.1 0.002
Pain 7.8 ± 4.0 4.3 ± 2.5 0.001
Stiffness 3.2 ± 1.7 2.2 ± 1.3 0.022
Function 25.4 ± 11.4 17.8 ± 8.5 0.006
* p-value < 0.05.
3.4. Expression Changes in Seven miRNAs in the Serum 6 and 18 Months after Surgery in
20 Patients Who Were Recruited in the 18-Month Follow-Up Study
To further investigate the changes in the expression of these seven miRNAs up to
18 months after HTO, serum specimens were collected in 20 patients who were recruited
and agreed to participate in an 18-month follow-up study. Their expression levels were
measured using RT-qPCR. The expression of all miRNAs was upregulated after 18 months
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from surgery as compared with that detected at 6 months after surgery following normal-
ization of values to SNORD61 expression. However, only two miRNAs (miR-424-5p and
miR-140-3p) were significantly upregulated up to 18 months after surgery after correcting
the p-values using the Bonferroni method (Table 8).




Fold Change Fold Change
has-miR-19b-3p 2.99 5.91 0.012
has-miR-29c-3p 2.3 4.44 0.016
has-miR-424-5p 5.13 8.6 0.003 *
has-miR-140-3p 3.09 8.48 0.003 *
has-miR-454-3p 2.6 3.57 0.027
has-miR-let-7e-5p 1.25 2.38 0.071
has-miR-885-5p 1.31 2.93 0.153
* Wilcoxon signed rank test. A Bonferroni corrected p-value < 0.0071 (0.05/7), which is marked with an asterisk,
was considered statistically significant.
4. Discussion
HTO is widely implemented as a joint preservation surgery in medial compartmental
OA and has been shown to improve articular cartilage after HTO in clinical studies [6,22].
Radiologic methods such as magnetic resonance imaging or second-look arthroscopic
evaluation after HTO are used to assess cartilage repair process [23]. However, these
evaluation techniques are expensive or invasive.
Generally, complex cytokine interaction is involved in arthritic cartilage damage.
Proinflammatory cytokines (e.g., IL-1β, TNFα, IL-6, IL-15, IL-17, and IL-18) participate in
the turnover of cartilaginous matrix, stimulating chondrocytes to increase the production of
enzymes to enhance matrix degradation, mainly metalloproteinase, while IL-4, IL-10, and
IL-13 inhibit this process. These cytokines are released by damaged cells of cartilage, bone
tissue, and synovium and detected in the plasma and synovial fluid of patients. Genes
related to the cartilage destruction in OA have been known to regulate the expression of
cytokines [24]. Besides, the expression of these genes has been reported to be regulated by
circulating miRNAs [8,9].
Recently, advanced techniques exploiting novel circulating miRNAs have highlighted
the potential role of miRNAs as promising biomarkers, especially in relation to OA [8–11,25].
Cell-based or preclinical studies on OA have suggested that miRNAs were either diagnostic
or underlying causative factors [26]. Circulating miRNAs have been detected in body fluids,
and investigators have suggested their plausible effects on OA progression [27]. Non-
invasive detection of circulating miRNAs specific to certain diseases may be of considerable
help for disease diagnosis and prognosis. Therefore, we performed this study to identify
serum miRNAs as potential prognostic biomarkers after HTO in medial compartmental
OA and found significant changes in the expression patterns of certain miRNAs before and
after surgery.
Four miRNAs, namely, miR-19b-3p, miR-140-3p, miR-454-3p, and miR-let-7e-5p,
showed significant changes in their expression patterns in the validation study performed
6 months after HTO. Of these, only miR-140-3p was significantly upregulated up to
18 months after HTO. Therefore, miR-140-3p may be the most significant prognostic
biomarker, although the other three miRNAs could be candidate prognostic biomarkers
after HTO.
Both miR-9 and miR-140 families play important roles in normal cartilage develop-
ment, and their aberrant expression is known to be involved in the pathology of OA [27].
We did not include miR-140 family in our inflammatory microarray panel, which is most
commonly available in our country. Therefore, we added miR-140-3p in the validation
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phase. However, the expression changes in miR-9 and miR-140 may differ based on
specimen type (tissue, SF, or serum).
Circulating miR-19b-3p has been previously implicated with OA severity [27]. The
role of miR-19b-3p in inflammatory processes has been studied, and its clinical value as a
potential biomarker for early diagnosis and prognosis of inflammatory diseases has been
investigated [28]. Kong et al. reported the upregulation in the expression of miR-19b-3p in
knee OA and the potential of the combined measurement of miR-19b-3p and other miRNAs
for the diagnosis, and as a measure of severity of, knee OA [27]. Duan et al. recently found
the underlying mechanism, wherein miR-19b-3p attenuates interleukin-1 beta (IL-1β)-
induced extracellular matrix degradation and inflammatory injury in chondrocytes [29].
Consistent with previously published data about OA, miR-19b-3p has been related to
clinical and radiological improvements after HTO in our study.
Both miR-29c-3p and miR-424-5p identified in the profiling phase of our study showed
no significant fold changes in their expression patterns in the validation phase with 27 pa-
tients. Li et al. compared the expression of miRNAs in the SF between early- and late-stage
knee OA and found significant changes in miR-29c-3p levels among many SF miRNAs [30].
However, our study aimed at mixed OA patients (early and late; K-L grade II and III)
who underwent HTO and serum specimens. Therefore, we believe that miR-29c-3p is
not a relevant serum biomarker after HTO, although it may be related to OA progression.
Rousseau et al. evaluated the association between circulating miRNAs and knee OA in
women and reported no significant changes in miR-29c-3p levels, consistent with our
results [31]. Many studies have revealed the role of miR-424-5p in cell- or tissue-based
OA [32]. miR-424-5p expression was downregulated in cartilage-derived stem cells from
a degraded cartilage that led to reduced proliferation and changes in the differentiation
profile of stem cells, consequently contributing to homeostasis imbalance and OA-related
cartilage erosion. In our study, miR-424-5p expression was significantly upregulated
18 months after surgery as compared with that after 6 months from surgery. However,
we believe that it is not a relevant prognostic biomarker because we failed to notice any
significant fold change in its expression in the validation phase.
In addition to the above three identified miRNAs, four other previously known miR-
NAs were validated in 27 patients. The changes in clinical symptoms and radiological
measurements were measured to verify any clinical improvement after HTO. From these
seven miRNAs, four were identified as circulating miRNA signatures in the validation stage
and could be related to clinical and radiological improvements after HTO in medial com-
partmental OA knee [30]. These have been known to be circulating miRNAs differentially
expressed in OA. Among the seven miRNAs, one from the profiling stage (miR-19b-3p) and
three added at the validation stage (miR-140-3p, miR-454-3p, and miR-let-7e-5p) showed
significantly upregulated expression after 6 months from surgery as compared with that
prior to surgery. Therefore, our results were consistent with those of previous OA studies
that used serum specimens, especially for miR-140-3p [33]. As miR-140 has been known
as a major miRNA implicated in OA and highly and selectively expressed in the carti-
lage, it has been the focus of many studies [34–37]. miR-140-3p is a circulating miRNA in
the serum and related to OA. Target gene analysis of miR-140-3p revealed regulation of
metabolic processes in OA pathology and that miR-140-3p expression was consistently
downregulated in articular cartilage with OA severity [38]. miR-140-3p also plays a role in
IL-1β-stimulated OA chondrocytes and shows inverse correlation between miR-140-3p and
IL-1β-stimulated OA chondrocytes [39]. In our study, miR-140-3p expression was signifi-
cantly upregulated up to 18 months after HTO, suggestive of its potential as a prognostic
biomarker after HTO in medial compartmental knee OA. The level of miR-454-3p in the
serum has been previously evaluated in OA, but no reports related to knee OA are yet
published [40,41]. Although significant changes in circulating miR-454-3p level have been
previously observed, such effects have been related to many other conditions, including
tumour [42,43], inflammatory process [44,45], and nutrition [46]. Therefore, the role of
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miR-454 in prognosis after HTO in medial compartmental knee OA should be confirmed
with additional studies.
Aside from the miR-140 family, miR-let-7e-5p has been suggested as an important cir-
culating serum miRNA in OA [12]. In our study, miR-let-7e-5p expression was significantly
upregulated and was consistent with the clinical and radiological improvements after HTO.
This observation is in line with that of another study that identified miR-let-7e-5p as a
negative predictor of OA [9]. Kung et al. suggested an increase in circulating miR-let-7e-5p
level in patients with arthritis [12], while Beyer et al. revealed the downregulation in its
expression in patients with OA [9]. Taken together, miR-let-7e-5p could also be a prognostic
biomarker for OA improvement after HTO. However, previous reports are inconsistent,
and our finding was based on the clinical setting of HTO patients. Accordingly, further
studies are needed to eliminate any bias.
For clinical relevance, the possible correlation between clinical and radiological im-
provements and the expression of seven miRNAs was analysed in 27 patients. No direct
correlation was noted between expression changes in serum miRNAs and outcomes, prob-
ably owing to the small number of patients and the subjective nature of clinical scoring.
Our study has several limitations. In the profiling phase, we used an 84 miRNA
panel, which was available in our country, known to be primarily involved in inflammatory
processes. Therefore, only 84 miRNAs were screened in this phase. As a compensation
strategy, we included several important miRNAs reported to be related to OA progression
in the validation phase. Future studies in a larger patient cohort are needed to confirm
our findings, as only a small number of serum miRNAs have been analysed. Second,
no positive control was included in our study that may be needed, as the change in
each miRNA in the serum would be a result of the surgical procedure and not entirely
specific to HTO. In this direction, we compared not only preoperative and postoperative
expression levels of miRNAs but also clinical and radiologic improvements specific to
HTO. Third, the underlying mechanism between miRNAs and post-HTO prognosis was
not evaluated. We believe that our study provides a fundamental basis to identify potential
prognostic miRNAs on the basis of changes in their expression levels along with clinical
and radiological improvements after HTO in medial compartmental knee OA. Fourth,
some miRNAs which have been known as important OA-related miRNAs may have been
initially excluded because their expression may not have been significantly affected after
HTO. HTO is performed at a stage where further OA progression is inevitable, and its
effect is not to completely cure OA but to delay its progression through partial repair
process of damaged cartilage via realignment of mechanical axis. Therefore, we believe
that the change of miRNAs expression after HTO would be different from the physiologic
change in progression of OA Fifth, the radiographic semiquantitative evaluation before and
after HTO is a bit unprecise hence it is difficult to expect a direct correlation. It is thought
that more precise results would have been obtained if MRI had been performed in all
patients at final follow-up. Sixth, we could not completely exclude patients with mild OA
or degenerative diseases in other joints or spine but no symptoms or remarkable changes on
plain radiographs although we tried to rule out patients with degenerative diseases in other
joints through the inclusion criteria. Therefore, mild degenerative diseases undetected
among enrolled patients may have affected our results. Finally, this study focused on
serum miRNAs as a measure of improvement in OA after HTO. The measurement of
the expression of miRNAs involved in cartilage repair and degradation may be more
accurate and reliable in SF or cartilage tissue than in serum. However, to obtain SF or
cartilage tissue specimen is more invasive, difficult, and complicated as against serum
specimens that can be easily and more consistently obtained. Accordingly, we believe that
the identification of serum miRNAs related to cartilage repair as prognostic biomarkers is
of paramount significance.
miRNAs in body fluids have been used as potential biomarkers to evaluate OA
severity and progression in addition to clinical and radiological assessments. Our study is
the first to screen circulating miRNAs in the serum from patients with medial compartment
Diagnostics 2021, 11, 258 12 of 14
knee OA and identify a panel of serum miRNAs that can help evaluate improvements
in OA between before and after joint preservation surgery. Therefore, the present study
suggests the potential use of these serum miRNAs as prognostic biomarkers to predict
clinical improvement in cartilage repair after HTO in medial compartmental knee OA.
However, further studies are warranted to establish clinical implications of changes in the
expression of these miRNAs after HTO.
5. Conclusions
Four serum miRNAs—miR-19b-3p, miR-140-3p, miR-454-3p, and miR-let-7e-5p—were
significantly upregulated in the validation phase of our study and identified as potential
prognostic biomarkers in medial compartmental knee OA patients showing clinical and
radiological improvements after HTO. Of these, miR-140-3p level was significantly upregu-
lated up to 18 months after HTO, indicating that miR-140-3p may be the best prognostic
biomarker after HTO in medial compartmental knee OA. We believe that our results pro-
vide a novel perspective on circulating serum miRNAs to predict cartilage repair along
with clinical and radiological improvements after HTO.
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41. Kopańska, M.; Szala, D.; Czech, J.; Gabło, N.; Gargasz, K.; Trzeciak, M.; Zawlik, I.; Snela, S. MiRNA expression in the cartilage of
patients with osteoarthritis. J. Orthop. Surg. Res. 2017, 12, 51. [CrossRef]
42. Shao, N.; Xue, L.; Wang, R.; Luo, K.; Zhi, F.; Lan, Q. miR-454-3p is an exosomal biomarker and functions as a tumor suppressor in
glioma. Mol. Cancer Ther. 2019, 18, 459–469. [CrossRef]
43. Ren, L.; Chen, H.; Song, J.; Chen, X.; Lin, C.; Zhang, X.; Hou, N.; Pan, J.; Zhou, Z.; Wang, L.; et al. MiR-454-3p-mediated
Wnt/β-catenin signaling antagonists suppression promotes breast cancer metastasis. Theranostics 2019, 9, 449–465. [CrossRef]
[PubMed]
44. Erener, S.; Marwaha, A.; Tan, R.; Panagiotopoulos, C.; Kieffer, T.J. Profiling of circulating microRNAs in children with recent
onset of type 1 diabetes. JCI Insight 2017, 2, e89656. [CrossRef] [PubMed]
45. Templeton, E.M.; Lasse, M.; Pilbrow, A.P.; Cameron, V.A.; Pickering, J.W.; Hertzberg, D.; Frampton, C.M.; Endre, Z.H.; Richards,
A.M.; Doughty, R.N.; et al. Circulating microRNA-454-3p is associated with acute kidney injury in patients with acute decompen-
sated heart failure. Genet. Genom. 2019, 140, A13115.
46. Quintanilha, B.J.; Ferreira, L.R.P.; Ferreira, F.M.; Neto, E.C.; Sampaio, G.R.; Rogero, M.M. Circulating plasma microRNAs
dysregulation and metabolic endotoxemia induced by a high-fat high-saturated diet. Clin. Nutr. 2020, 39, 554–562. [CrossRef]
[PubMed]
